Lufotrelvir clinical trials
Also written PF-07304814.
How each study uses lufotrelvir is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- PF-07304814
- 5
Studies by the year they started
5 studies that test it; most in 2020 (3)
| Year | Studies |
|---|---|
| 2020 | 3 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 2
Pfizer (3) · National Institute of Allergy and Infectious Diseases (NIAID) (2)
Often tested with
Tested in the same studies.
Bamlanivimab (1) · Sotrovimab (1) · Cilgavimab and tixagevimab drug combination (1) · Ensovibep (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protease Inhibitors source
Studies
Open first, then newest update. How each study uses lufotrelvir is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]-PF-07304814 in Healthy ParticipantsCompletedPhase 1PfizerNCT05050682Written as PF-07304814
- PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)TerminatedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT05780541Written as PF-07304814
- ACTIV-3: Therapeutics for Inpatients With COVID-19CompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT04501978Written as PF-07304814
- First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.CompletedPhase 1PfizerNCT04535167Written as PF-07304814
- Single Ascending Dose Study of Intravenous Infusion of PF 07304814 in Healthy Adult ParticipantsCompletedPhase 1PfizerNCT04627532Written as PF-07304814
Codes
What other systems call lufotrelvir · ClinicalTrials.gg INT001565
- MeSH (NLM) C000714028lufotrelvirOne source NLM
- UNII (FDA) XJ51YOB1SCLUFOTRELVIRConfirmed FDA, NLM, Wikidata
- Wikidata Q106857003lufotrelvirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C183321LufotrelvirOne source FDA
- DrugBank DB16514One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000714028 | lufotrelvir | One source NLM |
| UNII (FDA) | XJ51YOB1SC | LUFOTRELVIR | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q106857003 | lufotrelvir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C183321 | Lufotrelvir | One source FDA |
| DrugBank | DB16514 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.